Abstract

Breast cancer (BC) remains the most frequently diagnosed cancer in women. A balance in the opposing actions of histone acetyltransferases (HATs) and histone deacetylases (HDACs) is necessary for epigenetic regulation of gene expression. Impairment in the balance between the actions of HATs and HDACs has been reported in the development of BC. By targeting histone and several non-histone proteins, histone deacetylase inhibitors (HDACi) can maintain the cellular acetylation profile and reverse the function of several proteins responsible for BC development. Preclinical and clinical data show that HDACi can evoke different anticancer mechanisms in distinct BC types.